Adverum Biotechnologies filed a stockholder reminder notice Sunday evening, applying pressure to shareholders who have not yet tendered into Eli Lilly's pending acquisition offer. The Redwood City clinical-stage firm is reminding holders of its $3.00 per share all-cash tender, a $114 million valuation that Lilly announced in October. The reminder filing marks the final phase before the tender closes, typically within days or weeks of such notices.
Adverum specializes in intravitreal gene therapy, a delivery mechanism that targets the back of the eye for chronic retinal diseases. The company's lead program, ADVM-022, treats wet age-related macular degeneration through a single injection designed to provide multi-year therapeutic effect. Lilly's interest centers on the platform technology and the clinical data package Adverum has generated, particularly in a therapeutic area where Lilly has limited presence but growing ambition. The tender offer bypasses the traditional merger vote structure, allowing Lilly to accelerate closing once it crosses the 90% tender threshold required under Delaware law.
The reminder notice matters because it signals Lilly expects to close this quarter, ahead of year-end tax planning windows for institutional holders. Adverum's stockholder base includes several biotech-focused hedge funds and crossover investors who have held through two years of clinical setbacks and a 72% share price decline from 2023 highs. The $3.00 offer represents a 53% premium to Adverum's undisturbed trading price the day before announcement, but sits 31% below the company's January 2024 trading levels. For Lilly, the acquisition adds a second gene therapy platform to complement its neurodegeneration pipeline, following its $1.4 billion Versanis Biosciences deal in June that brought a GLP-1 obesity asset.
Allocators should watch the tender expiration date, which Adverum will file in the next 48-72 hours if the reminder notice follows standard timelines. A successful close before year-end would position Lilly to integrate Adverum's 23-person clinical operations team into its Lilly Research Laboratories division in Q1 2026. The integration matters because Lilly has signaled it will run ADVM-022 through a pivotal trial starting mid-2026, contingent on FDA feedback expected in Q1. Separately, watch whether Lilly retains Adverum's Redwood City facility or consolidates operations into its San Diego gene therapy hub, a decision that typically surfaces 60-90 days post-close in SEC integration filings.
The reminder notice is the fact. Lilly wants the platform before calendar year-end, and Adverum's board wants the transaction closed before Q4 earnings season complicates the narrative. The tender will cross 90% within ten business days of this filing.